Please Wait
Applying Filters...
menu
    • menu
    Aspen API. More than just an API™

    Virtual Booth

    Contact Supplier

    Sharp is a leader in commercial packaging, clinical services, and sterile manufacturing.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-01-12

    Virtual Booth

    An Enquiry

    Suanfarma, at the Core of a Better Life.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    Tenofovir Alafenamide

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    ANALYTICAL

    PharmaCompass
    $ API Ref.Price (USD/KG) : 3,153Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 7Biktarvy

    02 6Descovy

    03 15Genvoya

    04 8Odefsey

    05 5Prezista/Prezcobix/Rezolsta/Symtuza

    06 5Revenue share - Symtuza

    07 5Stribild

    08 7Symtuza

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Prezista/Prezcobix/Rezolsta/Symtuza

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Johnson & Johnson

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 2,184

    2019 Revenue in Millions : 2,110

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Odefsey

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Odefsey

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,672

    2019 Revenue in Millions : 1,655

    Growth (%) : 1

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Genvoya

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 3,338

    2019 Revenue in Millions : 3,931

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Symtuza

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 488

    2019 Revenue in Millions : 379

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    05

    Brand Name : Descovy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Descovy

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 1,861

    2019 Revenue in Millions : 1,500

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    06

    Brand Name : Genvoya

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 3,338

    2019 Revenue in Millions : 3,931

    Growth (%) : -15

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    07

    Brand Name : Stribild

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Stribild

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 196

    2019 Revenue in Millions : 369

    Growth (%) : -47

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    08

    Brand Name : Symtuza

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Symtuza

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Elvitegravir, Cobicistat, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 488

    2019 Revenue in Millions : 379

    Growth (%) : 29

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    09

    Brand Name : Biktarvy

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Biktarvy

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2020 Revenue in Millions : 7,259

    2019 Revenue in Millions : 4,738

    Growth (%) : 53

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    10

    Brand Name : Genvoya

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    arrow
    ASPEN
    Not Confirmed

    Brand Name : Genvoya

    U.S.A
    arrow
    ASPEN
    Not Confirmed

    Gilead

    Bictegravir, Emtricitabine, Tenofovir Alafenamide

    Main Therapeutic Indication : Infectious Diseases

    Currency : USD

    2021 Revenue in Millions : 2,879

    2020 Revenue in Millions : 3,338

    Growth (%) : -14

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.